Ultragenyx Pharmaceutical Inc. cash flow to debt ratio of -36.52% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ultragenyx Pharmaceutical Inc.'s free cash flow has decreased 11.93% from $-421.68M last year to $-472.00M, signaling decreasing performance

Ultragenyx Pharmaceutical Inc.'s debt to equity ratio is -4.13, signaling that the company spent its equity and risk bankruptcy.

Ultragenyx Pharmaceutical Inc.'s debt to equity ratio is -4.13, signaling that the company spent its equity and risk bankruptcy.

Ultragenyx Pharmaceutical Inc. has negative EBITDA, making leverage ratio unreliable

Ultragenyx Pharmaceutical Inc.'s interest coverage ratio is -6.95, which means that the company struggles to meet interest obligations, signaling financial risk.

Ultragenyx Pharmaceutical Inc.'s profit margin has increased (-19.49%) in the last year from -101.60% to -81.79%, signaling increasing performance

Ultragenyx Pharmaceutical Inc.'s short-term assets of $951.00M exceed its short-term liabilities of $384.00M

Ultragenyx Pharmaceutical Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ultragenyx Pharmaceutical Inc.'s return on equity of 392.35%, is higher than 15.00%, indicating good performance

Ultragenyx Pharmaceutical Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ultragenyx Pharmaceutical Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Ultragenyx Pharmaceutical Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ultragenyx Pharmaceutical Inc. has negative free cash flow, indicating cash burn

Ultragenyx Pharmaceutical Inc.'s yearly earnings has decreased 1.02% since last year from $-569.18M to $-575.00M, signaling decreasing performance

Ultragenyx Pharmaceutical Inc.'s yearly revenue has increased 20.13% since last year from $560.23M to $673.00M, signaling increasing performance

ROIC -53.48% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ultragenyx Pharmaceutical Inc.'s 3-year revenue CAGR of 22.81% is positive, indicating growing revenue over the past 3 years

Ultragenyx Pharmaceutical Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Ultragenyx Pharmaceutical Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Ultragenyx Pharmaceutical Inc. has insufficient data to evaluate this check.

Ultragenyx Pharmaceutical Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ultragenyx Pharmaceutical Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ultragenyx Pharmaceutical Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ultragenyx Pharmaceutical Inc. is overvalued relative to its fair value price of -143.51 based on Earnings Fair Value model

Ultragenyx Pharmaceutical Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ultragenyx Pharmaceutical Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Ultragenyx Pharmaceutical Inc. has a price-to-sales ratio of 3.81x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue